-
1.
公开(公告)号:US20240161519A1
公开(公告)日:2024-05-16
申请号:US18511998
申请日:2023-11-16
Applicant: TEMPUS LABS, INC.
Inventor: Chi-Sing Ho , Tianyou Luo , Ameen Salahudeen , Luca Lonini
CPC classification number: G06V20/698 , G06T3/40 , G06T7/10 , G06V10/46 , G06V20/695 , G16H30/40 , G06T2207/20132
Abstract: A computer-implemented method, computing system and computer-readable medium include receiving training data and training a machine learning model to generate a cell expression map. A computer-implemented method, computing system and computer-readable medium includes receiving a histology image and a cell segmentation map and processing them using a trained machine learning model.
-
2.
公开(公告)号:US20240087747A1
公开(公告)日:2024-03-14
申请号:US18513153
申请日:2023-11-17
Applicant: Tempus Labs, Inc.
Inventor: Carin Fishel Queen , Hailey Lefkofsky , Ashraf Hafez , Julian Habib , Caroline Epstein
Abstract: A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.
-
3.
公开(公告)号:US20240079086A1
公开(公告)日:2024-03-07
申请号:US17902558
申请日:2022-09-02
Applicant: TEMPUS LABS, INC.
Inventor: Charles Jaros , Nayeem Qadir , Isaiah Simpson , Marc Wielansky
Abstract: The following relates generally to determining genomic biomarkers from biological data (e.g., a read of a nucleic acid, or an image, such as an image of a slide). In some embodiments, a transform orchestrator: (i) receives an order to transform biological data to one or more genomic biomarkers; (ii) selects a transform for deriving each of the received one or more genomic biomarkers; (iii) associates each selected transform with a cloud computing platform; (iv) executes instructions for each selected transform; (v) communicates an operational status of each selected transform; (vi) stores the genomic biomarker output from each selected transform; and (vii) provides a notification of a final operational status of each selected transform.
-
公开(公告)号:US20240076744A1
公开(公告)日:2024-03-07
申请号:US18261985
申请日:2022-01-21
Applicant: Tempus Labs, Inc.
Inventor: Richard Blidner , Eric Leon Harness
CPC classification number: C12Q1/6886 , G06N20/10 , G16B20/20 , G16B25/10 , G16B40/20 , G16H20/00 , G16H50/20 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156
Abstract: Methods, systems, and software are provided for detecting gene fusions in a subject with a cancer condition through mRNA boundary analysis of next generation sequencing of a transcriptome or relevant part thereof. Methods, systems, and software are provided for detecting splice variants in a subject with a cancer condition through mRNA boundary analysis of next generation sequencing of a transcriptome or relevant part thereof. Methods, systems, and software are provided for evaluating the complexity of an RNA-seq sequencing reaction through mRNA boundary analysis. Generally, the methods described herein include obtaining sequences of mRNA molecules for a plurality of genes in a sample of a subject. For each gene, an RNA boundary distribution including relative abundance value for each respective RNA boundary sub-sequence of the gene is determined from the plurality of sequences. These abundance values are evaluated using one or more models to provide the analyses described herein.
-
公开(公告)号:US11848107B2
公开(公告)日:2023-12-19
申请号:US17558479
申请日:2021-12-21
Applicant: Tempus Labs, Inc.
Inventor: Ashraf Hafez , Martin Christian Stumpe , Nike Beaubier , Daniel Neems , Caroline Epstein , Adrian William George Lange
CPC classification number: G16H50/30 , G16B20/00 , G16B25/10 , G16B30/00 , G16H10/60 , G16H20/00 , G16H50/20
Abstract: Systems and methods are provided for predicting metastasis of a cancer in a subject. A plurality of data elements for the subject's cancer is obtained, including sequence features comprising relative abundance values for gene expression in a cancer biopsy of the subject, optional personal characteristics about the subject, and optional clinical features related to the stage, histopathological grade, diagnosis, symptom, comorbidity, and/or treatment of the cancer in the subject, and/or a temporal element associated therewith. One or more models are applied to the plurality of data elements, determining one or more indications of whether the cancer will metastasize. A clinical report comprising the one or more indications is generated.
-
公开(公告)号:US20230272489A1
公开(公告)日:2023-08-31
申请号:US18300253
申请日:2023-04-13
Applicant: Tempus Labs, Inc.
Inventor: Ameen Salahudeen , Verónica Sánchez Freire , Brandon L. Mapes
IPC: C12Q1/6886 , C12N5/071 , G16H50/30 , C12M1/32 , G01N33/50 , G16B20/20 , C12N5/09 , C12Q1/02 , C12Q1/6806 , C12Q1/6816
CPC classification number: C12Q1/6886 , C12N5/0691 , G16H50/30 , C12M23/12 , G01N33/5091 , G16B20/20 , C12N5/0693 , C12Q1/025 , C12Q1/6806 , C12Q1/6816 , C12N2500/25 , C12N2527/00 , C12N2521/10 , C12N2509/10 , C12N2501/117 , C12N2501/11 , C12N2501/119 , C12N2501/999 , C12N2501/998 , C12N2533/54 , C12N2533/52 , C12N2533/90 , C12N2501/33 , C12Q1/6844
Abstract: Provided herein are novel organoid culture media, organoid culture systems, and methods of culturing tumor organoids using the subject organoid culture media. Also provided herein are tumor organoids developed using such organoid culture systems, methods for assessing the clonal diversity of the tumor organoids, and methods for using such tumor organoids, for example, for tumor modelling and drug development applications. In particular embodiments, the tumor organoid culture media provided herein is substantially free of R-spondins (e.g., R-spondin1).
-
公开(公告)号:US11741365B2
公开(公告)日:2023-08-29
申请号:US16412362
申请日:2019-05-14
Applicant: TEMPUS LABS, INC.
Inventor: Aly Azeem Khan
Abstract: A generalizable and interpretable deep learning model for predicting microsatellite instability from histopathology slide images is provided. Microsatellite instability (MSI) is an important genomic phenotype that can direct clinical treatment decisions, especially in the context of cancer immunotherapies. A deep learning framework is provided to predict MSI from histopathology images, to improve the generalizability of the predictive model using adversarial training to new domains, such as on new data sources or tumor types, and to provide techniques to visually interpret the topological and morphological features that influence the MSI predictions.
-
公开(公告)号:US11715565B2
公开(公告)日:2023-08-01
申请号:US16679054
申请日:2019-11-08
Applicant: Tempus Labs, Inc.
Inventor: Ashraf Hafez , Caroline Epstein
Abstract: Systems and methods are provided for implementing a tool for evaluating an effect on an event, such as a medication or treatment, on a subject's condition, using a propensity model that identifies matched treatment and control cohorts within a base population of subjects. A propensity value threshold, which can be obtained based on user input, can be used to adjust the selection of subjects for treatment and control cohorts. The tool allows analyzing features of the subjects in the treatment and control groups, and further allows for evaluation and comparison of survival objectives of subjects in the treatment and control groups.
-
9.
公开(公告)号:US11699507B2
公开(公告)日:2023-07-11
申请号:US17382343
申请日:2021-07-22
Applicant: Tempus Labs, Inc.
Inventor: Hailey Lefkofsky , Ashraf Hafez , Julian Habib , Carin Fishel , Caroline Epstein
IPC: G16H50/70 , G16H50/20 , G06K9/62 , G16H10/60 , G06N20/00 , G06F17/18 , G16H30/00 , G16H80/00 , G06F21/62 , G16H10/20 , G06F18/22 , G06F18/24 , G06F18/214 , G06F18/2115 , G06F18/243 , G06N5/01 , G06N5/00
CPC classification number: G16H10/20 , G06F17/18 , G06F18/214 , G06F18/2115 , G06F18/22 , G06F18/24 , G06F18/24323 , G06F21/62 , G06N5/01 , G06N20/00 , G16H10/60 , G16H30/00 , G16H50/20 , G16H50/70 , G16H80/00
Abstract: A system and method for analyzing a data store of de-identified patient data to generate one or more dynamic user interfaces usable to predict an expected response of a particular patient population or cohort when provided with a certain treatment. The automated analysis of patterns occurring in patient clinical, molecular, phenotypic, and response data, as facilitated by the various user interfaces, provides an efficient, intuitive way for clinicians to evaluate large data sets to aid in the potential discovery of insights of therapeutic significance.
-
公开(公告)号:US20230197269A1
公开(公告)日:2023-06-22
申请号:US17800492
申请日:2021-02-18
Applicant: Tempus Labs, Inc.
Inventor: Robert Tell , Jerod Parsons , Stephen J. Bush , Aly A. Khan , Ariane Lozac'hmeur , Denise Lau
IPC: G16H50/20 , A61K31/513 , A61K31/337 , A61K33/243 , G16H10/40 , G16H50/70 , C07K16/22 , A61K45/06
CPC classification number: G16H50/20 , A61K31/337 , A61K31/513 , A61K33/243 , C07K16/22 , G16H10/40 , G16H50/70 , A61K45/06
Abstract: Methods, systems, and software are provided for determining whether a subject is afflicted with an oncogenic pathogen. Nucleic acids from a biological sample of the subject are hybridized to a probe set that includes probes for human genomic loci and for genomic loci of oncogenic pathogens. Sequence reads of the hybridized nucleic acid are obtained and it’s determined whether each sequence read aligns to a human reference genome. For each sequence read that fails to align to the human reference genome, it’s determined whether the sequence read aligns to a reference genome of an oncogenic pathogen. Sequence reads that both (i) fail to align to the human reference genome and (ii) align to a reference genome of an oncogenic pathogen are tracked, thereby obtaining a sequence read count for the oncogenic pathogen. The sequence read count is used to ascertain whether the subject is afflicted with the oncogenic pathogen.
-
-
-
-
-
-
-
-
-